Corey Schuler, PhD, FNP, CNS & Allison Sayre, MSN, WHNP
A 41-year-old woman presents with a quiet but persistent shift in her physiology. Her cycles have gradually disappeared over the past 18–24 months. What began as irregularity has progressed to complete amenorrhea. Alongside this, she reports intermittent heat intolerance, disrupted sleep, and a level of fatigue that feels disproportionate to her lifestyle. She remains active, eats well, and describes herself as “doing all the right things,” yet her recovery is slower, her energy less reliable, and her sense of resilience diminished.
At first glance, this presentation feels familiar. The reflex is to consider early menopause or primary ovarian insufficiency. After all, amenorrhea and vasomotor symptoms often point in that direction. But there is a subtle mismatch. The timeline feels early. The fatigue feels deeper. Labs independently are for the most part normal, but the overall pattern gives clues and suggests that something upstream may be shaping the signal.
Looking at the Labs Differently
Initial labs return largely within conventional reference ranges, but closer inspection reveals a different story:
- TSH: 0.37 mIU/L (reference range 0.35–5.0)
- Free T4: 0.9 ng/dL (reference range 0.70–1.71)
- LH: 2.2 IU/L (reference range 2–10)
- FSH: 2.7 IU/L (reference range 2–10)
- Estradiol: 22 pg/mL (reference range approximately 54.5–544.8 pg/mL)
- Prolactin: 18.3 ng/mL (reference range approximately 4.7–23.6 ng/mL)
- IGF-1: 190 ng/mL (reference range approximately 229–382 ng/mL)
Nothing here is overtly alarming. Each value independently sits within or near the lower end of its respective range. In isolation, these numbers might easily be interpreted as “normal,” particularly in a patient whose symptoms could be attributed to life stage or stress, but taken together, a pattern begins to emerge.
Estradiol is low, yet LH and FSH are not meaningfully elevated. In a typical ovarian transition, declining estrogen prompts the brain to increase signaling to the ovaries. Here, that response is notably absent. Instead of compensating, gonadotropin output remains low, pointing away from primary ovarian decline and toward reduced upstream signaling. In practical terms, her symptoms still reflect low estrogen, but the driver is not ovarian exhaustion. It is a quieter pattern of central downregulation, where the hypothalamus and pituitary are simply not asking the ovaries to produce more. [1]
Thyroid markers show a similar pattern. Free T4 sits at the lower end of the range, yet TSH does not rise as expected. In primary thyroid conditions, TSH typically increases in response to lower thyroid hormone levels. Here, that signal appears blunted. The result is a subtle mismatch, where TSH appears inappropriately low relative to free T4. In the context of fatigue and other low-output signals, this pattern raises concern for reduced central drive rather than a primary thyroid issue. [1]
IGF-1 was drawn, as the Endocrine Society recommends that adults with suspected hypothalamic-pituitary dysfunction or other pituitary hormone deficits be evaluated for growth hormone deficiency, noting that a low IGF-1 increases the likelihood of the diagnosis. In this case, IGF-1 is on the lower side for age. On its own, this is easy to overlook. In the context of other low-output signals, however, it reinforces a broader pattern of under-signaled growth and repair. While not diagnostic, it raises suspicion for reduced central drive. [2]
Individually, these findings are easy to dismiss. Collectively, they suggest something different, and that is that this is not overt ovarian failure, but it is a pattern of reduced signaling across multiple axes.
A Pattern of Downregulated Output
Viewed through an Energy Allocation System, this case begins to look less like a primary endocrine disorder and more like a system operating with constrained output. The hypothalamic-pituitary axes are not necessarily failing outright, but they are simply dialing back. [3]
In this case, the HPG axis is producing less stimulation to the ovaries, the HPT axis is maintaining thyroid hormone in range (but without strong upstream drive), and the growth hormone axis appears quiet relative to physiologic demand.
This is not collapse, but it is conservation. And importantly, this pattern can present with symptoms that closely resemble menopause, even when the underlying driver is different.
When More Clarity Is Needed
At this stage, before even discussing magnetic resonance imaging (MRI), the case already looks like partial hypopituitarism. The patient appears to have central hypogonadism, likely early-stage central hypothyroidism, and possible growth hormone deficiency. The next step is not to guess, but to test pituitary reserve more rigorously. That is where the second blood test becomes essential.
An insulin tolerance test (ITT) was selected. This test creates a controlled physiologic stressor, allowing assessment of how the system responds when demand increases. Specifically, it evaluates the ability to mount a growth hormone and cortisol response under hypoglycemic conditions. The expectation is not perfect numbers, but adaptability. [2][4]
The results were as follows:
|
Time (minutes) |
Glucose (mg/dL) |
Cortisol (mcg/dL) |
Growth Hormone (ng/mL) |
|
0 |
88 |
14.2 |
0.07 |
|
30 |
34 |
14.2 |
0.07 |
|
45 |
45 |
18.7 |
0.10 |
|
60 |
47 |
20.7 |
0.10 |
|
90 |
63 |
15.6 |
<0.03 |
|
120 |
67 |
10.1 |
<0.03 |
The Unexpected Finding
Despite adequate hypoglycemic stimulus, growth hormone output remained minimal throughout the test. Cortisol, however, responded appropriately. This distinction is subtle but important. It suggests that not all axes are equally affected. The system retains some capacity for stress response, while other pathways, particularly those tied to growth, repair, and long-term investment, remain suppressed.
In practical terms, this reinforces the earlier observation, and that is that the body is prioritizing short-term survival over long-term restoration.
What If Imaging Is Normal?
At this stage, imaging often becomes the next step. But a normal MRI does not rule out the pattern already seen in the labs. Even without a visible pituitary lesion, the physiology remains the same. Low estrogen with low gonadotropins, blunted growth hormone response, and subtle thyroid mismatch still point to reduced central signaling. What changes is not the pattern, but the explanation behind it.
Without a structural finding, the focus shifts toward broader possibilities such as hypothalamic suppression, prior injury, chronic stress signaling, or early-stage pituitary dysfunction not yet visible on imaging. In other words, the case moves from a question of compression to one of regulation. [2][4]
From a management standpoint, conventional care may still consider hormone replacement based on clinical context and severity. Central thyroid patterns are typically managed using free T4 rather than TSH as a guide, and gonadal or growth hormone support may be appropriate in select cases. [2][4]
At the same time, a normal MRI creates space for a parallel question: If structure is intact, what is shaping the signal?
Reframing the Case
At this point, it would be easy to shift fully into a diagnostic framework. Labels such as “central hypogonadism” or “growth hormone deficiency” could reasonably be applied. But stepping back, the broader pattern remains more informative. This is a system that has gradually reduced output across multiple domains. Not abruptly, and not randomly, but in a coordinated way.
From an integrative perspective, this raises a different set of considerations:
- What signals led the system to downregulate?
- Is this pattern reversible with restoration of perceived safety and capacity?
- Which interventions expand resilience, rather than simply replacing output?
These questions do not replace conventional evaluation. They sit alongside it.
Opening the Door to a Different Approach
Not every case like this will require advanced testing. In fact, many patients present earlier in this trajectory, when labs are “normal” and symptoms are just beginning to accumulate. Recognizing the pattern at that stage creates an opportunity.
Instead of waiting for more definitive dysfunction, clinicians can begin to support:
- Energy availability and metabolic stability
- Sleep quality and circadian rhythm
- Stress perception and recovery capacity
- Nutrient sufficiency for endocrine signaling
- Appropriate exercise relative to recovery
These interventions do not force the system to produce more. They create the conditions under which production becomes appropriate again.
The Clinical Takeaway
Amenorrhea in the early 40s does not always reflect ovarian exhaustion. When low estrogen is paired with low or low-normal gonadotropins, and especially when accompanied by subtle shifts in thyroid and growth hormone signaling, it may reflect a broader pattern of central downregulation.
These cases often sit in the gray zone. Labs are near range, symptoms are real but not extreme, and the default approach is often reassurance. But this is precisely where pattern recognition matters most. Because by the time the system requires dynamic testing to reveal its limitations, the process has likely been in motion for some time.
The earlier question is not “which gland is failing,” but rather: What is the system responding to, and what would allow it to expand again?
Disclaimer:
The information provided is for educational purposes only. Consult your physician or healthcare practitioner if you have specific questions before instituting any changes in your daily lifestyle including changes in diet, exercise, and supplement use.
Corey Schuler, PhD, FNP, CNS has dedicated his career to advancing the science and clinical art of integrative medicine and serves as director of medical affairs for Allergy Research Group. He is a family nurse practitioner and practices holistic primary care at Synergy Family Physicians in White Bear Lake, Minnesota.
Allison Sayre, MSN, WHNP is a board-certified women’s health nurse practitioner with advanced expertise in hormonal health, integrative gynecology, and patient-centered care across the lifespan. She holds a Master of Science in Nursing and has served as both a clinical provider and educator in functional and conventional women’s health settings. At ARG, Allison contributes to medical education, clinical protocol development, and strategic content that supports the evolving needs of women's healthcare practitioners.
